Carbiotix to evaluate new enzyme supplied by potential strategic partner
Carbiotix (publ) ("Carbiotix") announces today that the company will begin a comprehensive evaluation of a new enzyme in Q2 supplied by a potential strategic partner. This new enzyme has the potential to accelerate achieving FDA GRAS No Objection and EFSA Novel Foods status in the US and EU respectively for AXOS food ingredients, supplements and our planned medical foods however will shift the time plan of our ongoing GRAS Self Affirmation process for AXOS.Kristofer Cook, CEO for Carbiotix, comments“We have recently become aware of a new enzyme in the pre-launch phase that, after an